News
Public · Published
Moderna (MRNA) Q3 earnings report preview: what to look for
Moderna is scheduled to report its third-quarter earnings this Friday before market hours. Analysts expect revenue to fall 12.8% year on year, a smaller decline than the 45.4% drop in the same quarter last year. Estimates have generally been reconfirmed over the past 30 days.
Published:
Updated:
What happened
Moderna is scheduled to report its third-quarter earnings this Friday before market hours. Analysts expect revenue to fall 12.8% year on year, a smaller decline than the 45.4% drop in the same quarter last year. Estimates have generally been reconfirmed over the past 30 days.
Confirmed
Global impact / market context
The report will show whether Moderna’s revenue decline is narrowing as analysts expect. Revenue results and earnings per share, a measure of profit allocated to each share, could change views of the company’s near-term business performance and influence investor decisions about holding or buying its shares.
Analyst inference
Recent results among therapeutics companies were mixed: Biogen reported 10.6% revenue growth and beat estimates by 6.4%, while Myriad Genetics’ revenue fell 1.5% but exceeded estimates by 6.1%. This offers sector context, but does not establish what Moderna will report.
Confirmed
What to watch
- Moderna’s earnings release this Friday before market hours, including whether reported revenue matches the expected 12.8% year-on-year decline. Confirmed
- Whether Moderna’s reported earnings per share beat or miss analysts’ estimates, since the article notes a beat last quarter but gives no current forecast. Analyst inference
- How Moderna’s revenue compares with the sharper 45.4% decline in the same quarter last year, which will indicate whether the downturn has eased. Analyst inference